spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  VR1 

 HSMN NewsFeed - 22 May 2026
AbbVie Announces Positive CHMP Opinion for MAVIRET(R) (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 May 2023
Sobi to Acquire CTI BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 May 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET(R) (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 23 Jun 2017
AbbVie Receives CHMP Positive Opinion for MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Apr 2017
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2017
Ascletis Raises US$100 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Dec 2016
AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Sep 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jul 2016
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Apr 2016
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2016
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
Biopharmaceuticals
 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 28 Sep 2015
AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2014
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Apr 2014
Gilead’s Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2014
European Commission Grants Marketing Authorization for Gilead’s Sovaldi(R) (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead’s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2013
Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 2 Nov 2007
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2007
Renovis Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2007
Evotec to Acquire Renovis, Seek NASDAQ Listing
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jun 2007
Renovis Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2007
President and CEO of Advanced Viral Research Corp. Signs on for an Additional Two Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2007
Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2007
Renovis Restructures to Focus on Advancing Its Neurological and Inflammatory Disease Programs Into Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2007
Renovis Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2006
NXY-059 Does Not Meet Efficacy Endpoints in Phase III Trial for Acute Ischemic Stroke
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Oct 2006
Human Genome Sciences Reports Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon(TM) with Ribavirin in Treatment-Naive Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2006
Advanced Viral Research (ADVR) Names Abbott Veteran Angelo S. Botter to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 May 2006
Renovis Names Donald R. Joseph as Senior Vice President, Corporate Development and General Counsel
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 22 additional stories matching:
VR1
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!